Infanrix Penta (diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) vaccine (adsorbed))
- Region
- 🇪🇺 EU
- Active substance
- diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) vaccine (adsorbed)
- Company
- GlaxoSmithKline Biologicals S.A.
- Status
- Lapsed
- Therapeutic area
- Hepatitis B; Tetanus; Immunization; Whooping Cough; Poliomyelitis; Diphtheria
- EU approval
- Mon 23 Oct 2000
- Application
- EMEA/H/C/000295
- ATC
- J07CA12
- Official record
- www.ema.europa.eu
Indication
Infanrix Penta is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B and poliomyelitis.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Infanrix Hexa Authorised · GlaxoSmithKline Biologicals S.A.
- 🇪🇺 Tritanrix HepB Lapsed · GlaxoSmithKline Biologicals S.A.
Follow Infanrix Penta
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.